2022 STOPCAP M1 Collaborators meeting


Thank you to those who were able to attend our recent STOPCAP meeting during ESMO in Paris.

We found the discussions enormously helpful for our understanding of the implications of our docetaxel efficacy and surrogate outcome results.

It was also great to have the opportunity to explain our planned approach to assessing the efficacy of second-generation anti-androgens and to validating the surrogacy results.

On the day we had the following presentations:

Jayne Tierney    Introduction to STOPCAP M1

Susan Halabi     Identifying reliable early surrogate outcomes for overall survival in mHSPC: 1st STOPCAP surrogacy

Claire Vale         Defining which men with mHSPC benefit from docetaxel: First STOPCAP IPD meta-analysis results

Jayne Tierney    More precisely assessing the effects of 2nd generation anti-androgens

David Fisher      Maximizing the value of STOPCAP IPD using cutting-edge methodology:
                          The need for detailed, consistent and accessible IPD


The results presented by Claire Vale and Susan Halabi have also been presented at ASCO and ESMO in 2022 and links to the abstracts are below.


Vale et al: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.5070

Halabi et al: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.5006


Halabi et al: https://doi.org/10.1016/j.annonc.2022.07.1507


We will keep you posted about the status of the related publications.  If you have any questions regarding the meeting, or STOPCAP in general, please do not hesitate to get in touch.

Email: mrcctu.stopcapm1@ucl.ac.uk